SCHEDULE: Janus Henderson Discloses 11.3% Stake in Benitec Biopharma

Janus Henderson Group plc and its affiliates reported beneficial ownership of 11.3% of Benitec Biopharma Inc.'s common stock as of June 30, 2025.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, reported beneficial ownership of 25,600,210 shares of Benitec Biopharma Inc. common stock.
• This represents 11.3% of the class of securities for Janus Henderson Group plc.
• Janus Henderson Group plc holds shared voting and shared dispositive power over these shares.
• Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based investment company and indirect subsidiary of Janus Henderson Group plc, separately reported beneficial ownership of 2,193,481 shares.
• The Master Fund's stake represents 8.6% of the class of securities and is included within the broader Janus Henderson Group plc's reported ownership.
• The filing is an Amendment No. 8 to a Schedule 13G, indicating an update to a previously disclosed beneficial ownership position.

Sentiment

Score: 6

Explanation: The filing indicates a significant beneficial ownership stake by a reputable investment firm, Janus Henderson, which can be interpreted as a vote of confidence in Benitec Biopharma. However, the filing itself is a routine disclosure of ownership and does not contain operational or financial performance details.

Positives

• Significant institutional investment by Janus Henderson Group plc, holding 11.3% of common stock, indicates confidence from a major asset manager.
• Janus Henderson Biotech Innovation Master Fund Ltd's 8.6% stake further reinforces institutional interest in Benitec Biopharma, particularly within the biotech sector.

Future Outlook

NA

Industry Context

This filing indicates continued or new institutional interest in the biotechnology and biopharmaceutical sector, specifically in Benitec Biopharma, from a major asset manager like Janus Henderson, which specializes in biotech innovation.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor sentiment and stock liquidity.

Key Dates

Keywords

Benitec Biopharma, Janus Henderson, Schedule 13G, beneficial ownership, common stock, institutional investment, biotech, biopharma